share_log

Cantor Fitzgerald Maintains Overweight on Orchard Therapeutics, Raises Price Target to $15

Benzinga ·  Mar 28, 2023 07:07

Cantor Fitzgerald analyst Pete Stavropoulos maintains Orchard Therapeutics (NASDAQ:ORTX) with a Overweight and raises the price target from $3 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment